The Trump administration has moved forward with a federal reclassification of marijuana, a policy change that would alter how the drug is regulated under U.S. law. The Justice Department is involved in the rulemaking process, signaling that the change carries legal and regulatory weight beyond prior administrative proposals.

Under the current federal framework, marijuana is classified as a Schedule I controlled substance, placing it alongside drugs deemed to have no accepted medical use. The proposed reclassification would lower that designation, formally acknowledging marijuana's medical applications and potentially easing restrictions on research, prescribing, and commerce.

Public health experts note that reclassification could expand access to medical marijuana for patients and reduce barriers for clinical research that has long been hampered by the drug's Schedule I status. At the same time, questions remain about how federal agencies will implement the change and how it will interact with existing state-level marijuana laws.

For the business and investment communities, the reclassification represents a potentially transformative development. Cannabis companies have operated under significant financial constraints due to federal prohibition, including limited access to banking and the inability to deduct standard business expenses under federal tax law. A formal schedule change could begin to address some of those burdens.

The policy shift is not without political complications. Some conservatives have raised concerns about the administration's direction on drug policy, reflecting ongoing tensions within the Republican coalition over marijuana legalization and federal drug enforcement priorities.